An important scientific advance has just been recorded by Oncorad Group. For the first time, an African oncology center accesses the columns of the prestigious American review Advances in Radiation Oncologywith the publication of a research article dedicated to combined treatment of prostate cancer by high -flow dose (HDR) and external radiotherapy.
This pioneering work, conducted by the Oncorad Group’s research unit, based at the Casablanca Littoral clinic, marks unprecedented international recognition of Moroccan expertise in radiotherapy. The study was validated by a rigorous reading committee and praised for the quality of its results, comparable to the standards of the most advanced countries in the field.
Carried out on more than 120 patients with aggressive forms of prostate cancer, the study demonstrated the effectiveness of the protocol combining HDR curiousherapy and external radiotherapy, with a rate of remission reaching 92 % and an absence of relevant toxicity. This protocol, already recognized as a reference treatment in several industrialized countries, has been applied and evaluated in the Moroccan context with particularly convincing results.
The project is carried out by a team of high -level Moroccan researchers and clinicians, including Pr Redouane Samlali, founder of Oncorad Group, Dr. Hamza Samlali, main investigator of the project, Dr Najlaa Assaid, scientific coordinator, as well as medical physicists Youness Khobbaizi, Omar Hanicha, Mahdi Abou El Houda and Sanaa and Sanaa Nabil. The project also benefited from the scientific support of Pr Hassan Jouhadi, professor at the Faculty of Medicine of Casablanca, head of the department of oncology of CHU Casablanca and at the head of several academic research teams.
Read also: Oncorad Group strengthens its governance with the appointment of Meryem Chami to the post of Deputy Managing Director
This is the largest clinical series published to date in Africa and the region is led by this therapeutic approach. The study also includes several dozen foreign patients, highlighting the transnational work of work carried out and positioning Oncorad Group as a leading regional medical player.
This success is based on the work of the group’s research unit, a multidisciplinary structure bringing together oncologists, medical physicists and researchers. Committed to the development of innovative protocols adapted to local realities, it constitutes a strategic lever for the continuous improvement in the management of cancers in Morocco.
The cell is currently leading several projects on robot-assisted surgery, advanced radiotherapy techniques, as well as the genetic and biological dimensions of cancer. Its collaborative approach, anchored in a network of national and international partners, makes it a dynamic and future research platform.
The review Advances in Radiation Oncologypublished by Elsevier in collaboration with the American Society for Radiation ONCOLOGY (ASTRO), is a world reference in the field. With an impact factor of 2.7 and indexed in the largest scientific bases (Pubmed Central, Scopus, Web of Science, etc.), it values clinical work with high impact, especially in limited resources contexts.
By contributing to international scientific literature with data from the African field, Oncorad Group lays down the foundations for harmonization of therapeutic strategies in cancerology on a national and regional scale. This first milestone calls for other publications, other cooperation, and testifies to an ambitious dynamic where research becomes an essential engine of health progress.